Lawrentschuk N - Search Results

1

Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns.

Lawrentschuk N, Daljeet N, Ma C, Hersey K, Zlotta A, Fleshner N. Lawrentschuk N, et al. Int Urol Nephrol. 2011 Mar;43(1):31-7. doi: 10.1007/s11255-010-9772-1. Epub 2010 Jun 12. Int Urol Nephrol. 2011. PMID: 20544283

2

Implications of amyloidosis on prostatic biopsy.

Lawrentschuk N, Pan D, Stillwell R, Bolton DM. Lawrentschuk N, et al. Int J Urol. 2004 Oct;11(10):925-7. doi: 10.1111/j.1442-2042.2004.00921.x. Int J Urol. 2004. PMID: 15479305 Free article. Review.

3

Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.

Appu S, Lawrentschuk N, Grills RJ, Neerhut G. Appu S, et al. Among authors: lawrentschuk n. J Urol. 2005 Jul;174(1):140-2. doi: 10.1097/01.ju.0000161591.86721.e5. J Urol. 2005. PMID: 15947599 Clinical Trial.

4

The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.

Lawrentschuk N, Fleshner N. Lawrentschuk N, et al. BJU Int. 2009 Mar;103(6):730-3. doi: 10.1111/j.1464-410X.2008.08205.x. Epub 2009 Jan 14. BJU Int. 2009. PMID: 19154475 Review.

5

Current textbooks and anatomy of the prostate--a case for an update.

Lawrentschuk N, Lindner U, Fleshner N. Lawrentschuk N, et al. BJU Int. 2009 May;103(10):1319-22. doi: 10.1111/j.1464-410X.2009.08426.x. Epub 2009 Feb 23. BJU Int. 2009. PMID: 19239448 No abstract available.

6

Risk of developing prostate cancer in the future: overview of prognostic biomarkers.

Fleshner NE, Lawrentschuk N. Fleshner NE, et al. Among authors: lawrentschuk n. Urology. 2009 May;73(5 Suppl):S21-7. doi: 10.1016/j.urology.2009.02.022. Urology. 2009. PMID: 19375623 Review.

7

Severe irritant contact dermatitis causing skin ulceration secondary to a testosterone patch.

Lawrentschuk N, Fleshner N. Lawrentschuk N, et al. ScientificWorldJournal. 2009 May 20;9:333-8. doi: 10.1100/tsw.2009.45. ScientificWorldJournal. 2009. PMID: 19468653 Free PMC article.

8

Clinical stage I seminoma: the case for surveillance.

Lawrentschuk N, Fleshner N. Lawrentschuk N, et al. World J Urol. 2009 Aug;27(4):433-9. doi: 10.1007/s00345-009-0430-0. Epub 2009 Jun 11. World J Urol. 2009. PMID: 19517114 Review.

9

Health information quality on the internet in urological oncology: a multilingual longitudinal evaluation.

Lawrentschuk N, Abouassaly R, Hackett N, Groll R, Fleshner NE. Lawrentschuk N, et al. Urology. 2009 Nov;74(5):1058-63. doi: 10.1016/j.urology.2009.05.091. Epub 2009 Sep 16. Urology. 2009. PMID: 19758687

10

Therapeutic options following orchiectomy for stage I seminoma.

Lawrentschuk N, Fleshner NE. Lawrentschuk N, et al. Oncology (Williston Park). 2009 Aug;23(9):749-53. Oncology (Williston Park). 2009. PMID: 19777758 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

620 results

Search Page

Filters